These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 33206027)

  • 21. The critical role of neutrophil-endothelial cell interactions in sepsis: new synergistic approaches employing organ-on-chip, omics, immune cell phenotyping and
    Liu D; Langston JC; Prabhakarpandian B; Kiani MF; Kilpatrick LE
    Front Cell Infect Microbiol; 2023; 13():1274842. PubMed ID: 38259971
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of complement, C5a and its receptors in sepsis and multiorgan dysfunction syndrome.
    Flierl MA; Schreiber H; Huber-Lang MS
    J Invest Surg; 2006; 19(4):255-65. PubMed ID: 16835140
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Promising predictors of checkpoint inhibitor response in NSCLC.
    Alex F; Alfredo A
    Expert Rev Anticancer Ther; 2020 Nov; 20(11):931-937. PubMed ID: 32870120
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A new paradigm for the treatment of sepsis: is it time to consider combination therapy?
    Cross AS; Opal SM
    Ann Intern Med; 2003 Mar; 138(6):502-5. PubMed ID: 12639085
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sepsis Care Pathway 2019.
    Labib A
    Qatar Med J; 2019; 2019(2):4. PubMed ID: 31763206
    [No Abstract]   [Full Text] [Related]  

  • 26. Therapeutic potential of targeting the complement cascade in critical care medicine.
    Bhole D; Stahl GL
    Crit Care Med; 2003 Jan; 31(1 Suppl):S97-104. PubMed ID: 12544983
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of C5a-induced inflammation with preserved C5b-9-mediated bactericidal activity in a human whole blood model of meningococcal sepsis.
    Sprong T; Brandtzaeg P; Fung M; Pharo AM; Høiby EA; Michaelsen TE; Aase A; van der Meer JW; van Deuren M; Mollnes TE
    Blood; 2003 Nov; 102(10):3702-10. PubMed ID: 12881318
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Complement in allergy and asthma.
    Gerard NP; Gerard C
    Curr Opin Immunol; 2002 Dec; 14(6):705-8. PubMed ID: 12413519
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting Immune Cell Checkpoints during Sepsis.
    Patil NK; Guo Y; Luan L; Sherwood ER
    Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29135922
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sepsis in surgical patients: Personalized medicine in the future treatment of sepsis.
    Viktorsson SA; Turnbull IR
    Surgery; 2024 Aug; 176(2):544-546. PubMed ID: 38760228
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New strategies for treatment of infectious sepsis.
    Ward PA; Fattahi F
    J Leukoc Biol; 2019 Jul; 106(1):187-192. PubMed ID: 30821872
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Commensal microbiota contributes to predicting the response to immune checkpoint inhibitors in non-small-cell lung cancer patients.
    Zhang C; Wang J; Sun Z; Cao Y; Mu Z; Ji X
    Cancer Sci; 2021 Aug; 112(8):3005-3017. PubMed ID: 34028936
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel approaches to the development of anti-sepsis drugs.
    Lehmann C; Sharawi N; Al-Banna N; Corbett N; Kuethe JW; Caldwell CC
    Expert Opin Drug Discov; 2014 May; 9(5):523-31. PubMed ID: 24697209
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting immune checkpoints in hematological malignancies.
    Salik B; Smyth MJ; Nakamura K
    J Hematol Oncol; 2020 Aug; 13(1):111. PubMed ID: 32787882
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting Complement Pathways in Polytrauma- and Sepsis-Induced Multiple-Organ Dysfunction.
    Karasu E; Nilsson B; Köhl J; Lambris JD; Huber-Lang M
    Front Immunol; 2019; 10():543. PubMed ID: 30949180
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Staging and Personalized Intervention for Infection and Sepsis.
    Beckmann N; Salyer CE; Crisologo PA; Nomellini V; Caldwell CC
    Surg Infect (Larchmt); 2020 Nov; 21(9):732-744. PubMed ID: 32240042
    [No Abstract]   [Full Text] [Related]  

  • 37. Novel RNA interference-based therapies for sepsis.
    Kosovrasti VY; Lukashev D; Nechev LV; Amiji MM
    Expert Opin Biol Ther; 2014 Apr; 14(4):419-35. PubMed ID: 24397825
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Re-Evaluating Biologic Pharmacotherapies that Target the Host Response during Sepsis.
    Tuttle K; McDonald M; Anderson E
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31801287
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The PARP inhibitor olaparib exerts beneficial effects in mice subjected to cecal ligature and puncture and in cells subjected to oxidative stress without impairing DNA integrity: A potential opportunity for repurposing a clinically used oncological drug for the experimental therapy of sepsis.
    Ahmad A; Vieira JC; de Mello AH; de Lima TM; Ariga SK; Barbeiro DF; Barbeiro HV; Szczesny B; Törö G; Druzhyna N; Randi EB; Marcatti M; Toliver-Kinsky T; Kiss A; Liaudet L; Salomao R; Soriano FG; Szabo C
    Pharmacol Res; 2019 Jul; 145():104263. PubMed ID: 31071432
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A key role of C5a/C5aR activation for the development of sepsis.
    Riedemann NC; Guo RF; Ward PA
    J Leukoc Biol; 2003 Dec; 74(6):966-70. PubMed ID: 12960283
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.